Literature DB >> 8602364

Viral transactivators specifically target distinct cellular protein kinases that phosphorylate the RNA polymerase II C-terminal domain.

C H Herrmann1, M O Gold, A P Rice.   

Abstract

Phosphorylation of the carboxyl-terminal domain (CTD) of the largest subunit of RNA polymerase II has been implicated as an important step in transcriptional regulation. Previously, we reported that a cellular CTD kinase, TAK, is targeted by the human immunodeficiency virus transactivator Tat. In the present study, we analyzed several other transactivators for the ability to interact with CTD kinases in vitro. The adenovirus E1A and herpes simplex virus VP16 proteins, but not other transactivators tested, were found to associate with a cellular kinase activity that hyperphosphorylates the CTD. The interaction is dependent upon a functional activation domain of E1A or VP16, suggesting that the interaction with a CTD kinase is relevant for the transactivation function of these proteins. The CTD kinase activities that interact with E1A and VP16 are related to each other but distinct from TAK. The Tat-, E1A- and VP16-associated CTD kinase activities detected in our assay also appear unrelated to MO15, the catalytic component of the CTD kinase activity of the general transcription factor TFIIH. Thus, this study has identified a novel interaction between viral transactivators and a cellular CTD kinase and suggests that at least two CTD kinases may mediate responses to viral transactivators.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8602364      PMCID: PMC145661          DOI: 10.1093/nar/24.3.501

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  79 in total

1.  Transcription activation by the adenovirus E1a protein.

Authors:  J W Lillie; M R Green
Journal:  Nature       Date:  1989-03-02       Impact factor: 49.962

2.  Association of adenovirus early-region 1A proteins with cellular polypeptides.

Authors:  E Harlow; P Whyte; B R Franza; C Schley
Journal:  Mol Cell Biol       Date:  1986-05       Impact factor: 4.272

3.  GAL4-VP16 is an unusually potent transcriptional activator.

Authors:  I Sadowski; J Ma; S Triezenberg; M Ptashne
Journal:  Nature       Date:  1988-10-06       Impact factor: 49.962

4.  Functional dissection of VP16, the trans-activator of herpes simplex virus immediate early gene expression.

Authors:  S J Triezenberg; R C Kingsbury; S L McKnight
Journal:  Genes Dev       Date:  1988-06       Impact factor: 11.361

5.  Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product.

Authors:  S Y Kao; A F Calman; P A Luciw; B M Peterlin
Journal:  Nature       Date:  1987 Dec 3-9       Impact factor: 49.962

Review 6.  Multiple functional domains in the adenovirus E1A gene.

Authors:  E Moran; M B Mathews
Journal:  Cell       Date:  1987-01-30       Impact factor: 41.582

7.  Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product.

Authors:  P Whyte; K J Buchkovich; J M Horowitz; S H Friend; M Raybuck; R A Weinberg; E Harlow
Journal:  Nature       Date:  1988-07-14       Impact factor: 49.962

8.  Response of individual adenovirus promoters to the products of the E1A gene.

Authors:  C V Dery; C H Herrmann; M B Mathews
Journal:  Oncogene       Date:  1987       Impact factor: 9.867

9.  Messenger RNA synthesis in mammalian cells is catalyzed by the phosphorylated form of RNA polymerase II.

Authors:  D L Cadena; M E Dahmus
Journal:  J Biol Chem       Date:  1987-09-15       Impact factor: 5.157

10.  A unique structure at the carboxyl terminus of the largest subunit of eukaryotic RNA polymerase II.

Authors:  J L Corden; D L Cadena; J M Ahearn; M E Dahmus
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

View more
  34 in total

1.  The VP16 paradox: herpes simplex virus VP16 contains a long-range activation domain but within the natural multiprotein complex activates only from promoter-proximal positions.

Authors:  M Hagmann; O Georgiev; W Schaffner
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 2.  Transcriptional and posttranscriptional regulation of HIV-1 gene expression.

Authors:  Jonathan Karn; C Martin Stoltzfus
Journal:  Cold Spring Harb Perspect Med       Date:  2012-02       Impact factor: 6.915

3.  A human primary T-lymphocyte-derived human immunodeficiency virus type 1 Tat-associated kinase phosphorylates the C-terminal domain of RNA polymerase II and induces CAK activity.

Authors:  S Nekhai; R R Shukla; A Kumar
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Tat-associated kinase, TAK, activity is regulated by distinct mechanisms in peripheral blood lymphocytes and promonocytic cell lines.

Authors:  C H Herrmann; R G Carroll; P Wei; K A Jones; A P Rice
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

5.  Nuclear translocation and carboxyl-terminal domain phosphorylation of RNA polymerase II delineate the two phases of zygotic gene activation in mammalian embryos.

Authors:  S Bellier; S Chastant; P Adenot; M Vincent; J P Renard; O Bensaude
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

6.  Antiapoptotic function of Cdk9 (TAK/P-TEFb) in U937 promonocytic cells.

Authors:  S M Foskett; R Ghose; D N Tang; D E Lewis; A P Rice
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

7.  Cell cycle-regulated transcription by the human immunodeficiency virus type 1 Tat transactivator.

Authors:  F Kashanchi; E T Agbottah; C A Pise-Masison; R Mahieux; J Duvall; A Kumar; J N Brady
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 infection induces cyclin T1 expression in macrophages.

Authors:  Li-Ying Liou; Christine H Herrmann; Andrew P Rice
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

9.  AR1 is an integral part of the adenovirus type 2 E1A-CR3 transactivation domain.

Authors:  A C Ström; P Ohlsson; G Akusjärvi
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

Review 10.  Reversal of HIV-1 latency with anti-microRNA inhibitors.

Authors:  Hui Zhang
Journal:  Int J Biochem Cell Biol       Date:  2008-08-08       Impact factor: 5.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.